Literature DB >> 2522840

Possible involvement of the CD4 molecule in a late activation event on CD4+ T cell proliferation in the human autologous mixed lymphocyte reaction.

T Sakane1, S Takada.   

Abstract

CD4 monoclonal antibody (MoAb) was able to inhibit T cell proliferation induced in an autologous mixed lymphocyte reaction (AMLR). The effect of CD4 MoAb on cellular proliferation appears to be directly exerted on CD4+ T lymphocytes, and to be due to inhibition of a post-activation event, since the CD4+ T cell proliferation that occurs after an activation pulse of 24 h with autologous non-T cells could be inhibited when CD4 MoAb was added after, but not during, the pulse period, and the inhibition of autologous MLR-induced CD4+ T cell proliferation by CD4 MoAb was observed even if the Moab was added as late as 72 h after the initiation of culture. The presence of CD4 MoAb did not affect the production of interleukin 2 (IL-2). CD4 MoAb had, however, an inhibitory effect on the expression of IL-2 receptors, such that addition of exogenous IL-2 at the initiation of culture did not restore the AMLR-induced CD4+ T cell proliferation. These results indicate that the hindrance of the recognition of HLA class II products is not the only target of the CD4 MoAb effect in the autologous MLR. Rather, the binding of CD4 MoAb to CD4+ T cells interferes with a late event because it is capable of abolishing the proliferative activity of fully activated CD4+ T cells. The data are compatible with the idea that perturbation of the CD4 molecules can transmit a negative signal to CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522840      PMCID: PMC1542136     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Specificity and suppressor function of human T cells responsive to autologous non-T cells.

Authors:  T Sakane; I Green
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

Review 2.  The interleukin 2 receptor.

Authors:  K A Smith
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

Review 3.  Significance of self-recognition and interleukin-2 for immunoregulation, autoimmunity and cancer.

Authors:  J B Smith; N Talal
Journal:  Scand J Immunol       Date:  1982-10       Impact factor: 3.487

4.  Monoclonal antibody analysis of human T lymphocyte subpopulations exhibiting autologous mixed lymphocyte reaction.

Authors:  N K Damle; J A Hansen; R A Good; S Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

Review 5.  The autologous mixed-lymphocyte reaction.

Authors:  M E Weksler; C E Moody; R W Kozak
Journal:  Adv Immunol       Date:  1981       Impact factor: 3.543

6.  Responder cells in the human autologous mixed lymphocyte reaction.

Authors:  J S Smolen; T A Luger; T M Chused; A D Steinberg
Journal:  J Clin Invest       Date:  1981-12       Impact factor: 14.808

7.  A defect in the suppressor circuits among OKT4+ cell populations in patients with systemic lupus erythematosus occurs independently of a defect in the OKT8+ suppressor T cell function.

Authors:  T Sakane; H Kotani; S Takada; Y Murakawa; Y Ueda
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

8.  Specificity and function of a human autologous reactive T cell.

Authors:  P B Hausman; J D Stobo
Journal:  J Exp Med       Date:  1979-06-01       Impact factor: 14.307

9.  Autologous mixed lymphocyte culture reactions and generation of cytotoxic T cells.

Authors:  R A Vande Stouwe; H G Kunkel; J P Halper; M E Weksler
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

10.  Antibodies to membrane structures that distinguish suppressor/cytotoxic and helper T lymphocyte subpopulations block the mixed leukocyte reaction in man.

Authors:  E G Engleman; C J Benike; E Glickman; R L Evans
Journal:  J Exp Med       Date:  1981-07-01       Impact factor: 14.307

View more
  1 in total

1.  Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins.

Authors:  N Bonnefoy-Berard; B Verrier; C Vincent; J P Revillard
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.